Home/Kyverna Therapeutics/Peter Maag, PhD
PM

Peter Maag, PhD

Chief Executive Officer

Kyverna Therapeutics

Kyverna Therapeutics Pipeline

DrugIndicationPhase
KYV-101Lupus Nephritis (Systemic Lupus Erythematosus)Phase 1/2
KYV-201Undisclosed autoimmune indicationPreclinical